Back to top
more

Intellia Therapeutics (NTLA)

(Delayed Data from NSDQ)

$15.67 USD

15.67
8,845,931

+0.47 (3.09%)

Updated Jun 18, 2026 03:59 PM ET

After-Market: $15.63 -0.04 (-0.26%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.00%
2Buy18.14%
3Hold10.18%
4Sell5.72%
5Strong Sell3.11%
S&P50011.49%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value F Growth B Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 38% (153 out of 247)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Abhinab Dasgupta headshot

Beat the Market the Zacks Way: Oracle, Intellia, Pharming Group in Focus

by Abhinab Dasgupta

Even in a choppy market, Zacks' strategies are spotlighting winners like Oracle, Intellia, and Pharming Group, proving the value of a disciplined, research-driven approach.

Kanishka Das headshot

Can CRSP's In Vivo Pipeline Aid Long-Term Growth Beyond Casgevy?

by Kanishka Das

CRISPR Therapeutics pushes beyond Casgevy with in vivo programs like CTX310, CTX320 and plans for two more studies by 2025-end.

Kanishka Das headshot

CRISPR Therapeutics Gains 41.4% in 3 Months: How to Play the Stock

by Kanishka Das

CRSP surges 41.4% in three months, fueled by promising CTX310 study data and accelerating Casgevy sales.

Zacks Equity Research

Can Rising Casgevy Sales Aid CRISPR Therapeutics Post Q2 Earnings?

by Zacks Equity Research

CRSP's Casgevy records a 114% sales jump sequentially in Q2, fueling optimism for sustained revenues and long-term growth.

Santanu Roy headshot

Take the Zacks Approach to Beat the Markets: Digi Power X, RF Industries & Starbucks in Focus

by Santanu Roy

Zacks spotlights Digi Power X, RF Industries and Starbucks as standout gainers amid market volatility and economic uncertainty.

Zacks Equity Research

Intellia Q2 Loss Narrower Than Expected, Pipeline Progress in Focus

by Zacks Equity Research

NTLA posts narrower Q2 loss and beats on revenues, while advancing phase III studies for ATTR and HAE programs.

Zacks Equity Research

Intellia Therapeutics, Inc. (NTLA) Reports Q2 Loss, Beats Revenue Estimates

by Zacks Equity Research

Intellia Therapeutics (NTLA) delivered earnings and revenue surprises of +3.88% and +9.43%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Ahan Chakraborty headshot

BioCryst Pharmaceuticals Before Q2 Earnings: How to Play the Stock

by Ahan Chakraborty

BCRX gears up for Q2 results with Orladeyo growth in focus, but 2025 EPS forecasts dip as investors eye pipeline progress.

Ekta Bagri headshot

3 Genomics Stocks Worth Adding to Your Portfolio in 2025

by Ekta Bagri

CRISPR-based innovators like NTLA, EDIT and PRME are gaining traction as genomics reshapes the future of medicine and biotech

Santanu Roy headshot

Take the Zacks Approach to Beat the Markets: AngloGold Ashanti, Caterpillar & Hershey in Focus

by Santanu Roy

AU, CAT and HSY are standing out as Zacks' high-conviction picks, with each posting double-digit gains in recent weeks.